Heartbeam, Inc. (BEAT) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heartbeam, Inc. on September 10, 2024, reporting events occurring on September 9, 2024. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
The primary material change is the appointment of Timothy Cruickshank as Chief Financial Officer, effective September 9, 2024. Mr. Cruickshank previously served as CFO of ImpediMed from October 2019 through March 2024.
Management Commentary and Compensation Details
- Base Salary: $385,000 annually, paid in semi-monthly installments.
- Incentive Bonus: Eligible for a bonus up to 45% of annual base salary based on corporate goals.
- Equity Grant: Subject to Board approval, an option to purchase 400,000 shares of Common Stock will be granted under the 2022 Stock Plan. The exercise price is to be determined by the Board upon grant.
- Background: Mr. Cruickshank brings experience in transitioning a medical device company to a high-margin SaaS model.
Investor Verification Checklist
- Verify the final grant date and exercise price of the 400,000 stock options for Mr. Cruickshank.
- Review the specific corporate goals and objectives tied to the 45% incentive bonus.
- Confirm the absence of any related party transactions involving the new CFO.
- Check subsequent filings for any changes to the executive team or compensation structure.